Treatment of neuroendocrine tumors with somatostatin analogs

Pituitary

Volumn 9, Issue 3, 2006, Pages 249-256

  Janson, Eva Tiensuu ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hormone secretion; Neuroendocrine; Somatostatin analog; Treatment

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; GLUCOSE; KI 67 ANTIGEN; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; VAPREOTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE I 125;

ABDOMINAL PAIN; ACROMEGALY; ARTICLE; BRADYCARDIA; BRONCHUS CARCINOID; CARCINOID; CELL PROLIFERATION; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; ENTEROPATHY; FLUSHING; GALLSTONE; GASTRINOMA; GLUCAGONOMA; GROWTH INHIBITION; HORMONE SYNTHESIS; HUMAN; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULINOMA; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PANCREAS TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR BINDING; SMALL INTESTINE TUMOR; SOMATOSTATINOMA; STOMACH CARCINOID; STOMACH TUMOR; SYMPTOM; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH; VIPOMA;

ACTIVITIES OF DAILY LIVING; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL PROLIFERATION; HUMANS; NEUROENDOCRINE TUMORS; QUALITY OF LIFE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 33750970585     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-006-0271-4     Document Type: Article

References (54)

1. Klöppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors. The WHO classification. Ann NY Acad Sci 1014:13
2. Spread C, Berkel H, Jewell L, Jenkins H, Yakimets W (1994) Colon carcinoid tumors. A population based study. Dis Colon Rectum 37:482
3. Koura AN, Giacco GG, Curley SA, Skibber JM, Feig BW, Ellis LM (1997) Carcinoid tumors of the rectum. Effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 79:1294
4. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77
5. Patel YC (1997) Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Investig 20:348
6. de Herder WW, Lamberts SWJ (2002) Somatostatin and somatostatin analogues: Diagnostic and therapeutic uses. Curr Opin Oncol 14:53
7. Susini C, Buscail L (2006) Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol; in press
8. Grant M, Colliers B, Kumar U (2004) Agonist-dependent dissociation of human somatostatin receptor 2 dimers. J Biol Chem 279:36179
9. Thulin L, Samnegård H, Tydén G, Long DH, Efendic S (1978) Efficacy of somatostatin in a patient with carcinoid syndrome. The Lancet 2:43
10. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133
11. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM. (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 76:721
12. Grass P, Marbach P, Bruns C, Lancranjan I (1996) Sandostatin LAR (micorencapsulated octreotide acetate) in acromegaly: Pharmacokinetic and pharmacodynamic relationship. Metabolism 45:27
13. Öberg K, Kvols L, Chaplin M, Delle Fave G, de Herder W, Rindi G, Ruszniewski P, Woltering EA, Wiedenmann B. (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Ocnol 15:966
14. Schmid HA, Schoeffter P (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinol 80:47
15. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. (2004) Medullary thyroid carcinoma. Clin Endocrinol 61:299
16. Papotti M, Kumar U, Volante M, Pecchioni C, Patel Y. (2001) Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol 54:641
17. Mahler C, Verhelst J, De Longueville M, Harris M, Harris A. (1990) Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 33:261
18. Modigliani E, Cohen R, Joannidis S, Siame-Mourot C, Guliana JM, Charpentier G, Cassuto D, Bentata Pessayre M, Tabarin A, Roger P, Caron P, Guillasseau PJ, Lalau JD, Tourniaire J, Bayard F, Aufevre P, James-Deidier A, Calmettes C. (1992) Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol 36:183
19. Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR, Abbruzzese A, Lupoli G. (2000) Slow release lanreotide in combination with interferon-a2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85:983
20. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal A, Koss MN. (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with classification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22:934
21. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal A, Koss MN. (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with classification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22:934
22. Granberg D, Sundin A, Janson ET, Öberg K, Skogseid B, Westlin JE (2003) Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol 59:739
23. Granberg D, Eriksson B, Wilander E, Grimfjärd P, Fjällskog ML, Öberg K, Skogseid B (2001) Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 12:1383
24. Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. (2002) Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardio-Thorac Surg 21:913
25. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C, Solcia E (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis. Gastroenterol 116:532
26. Tsolakis AV, Portela-Gomes GM, Stridsberg M, Grimelius L, Sundin A, Eriksson BK, Öberg K, Janson ET (2004) Malignant gastric ghrelinoma with hypergastrinemia. J Clin Endocrinol Metab 89:3739
27. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L (2004) Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 343:551
28. Frykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL (2004) Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 39:621
29. Janson ET, Öberg K (2003) Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment. Cancer Chemother Biol Response Modif 21:535
30. Reubi JC (2004) Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinol 80:966
31. Kvols LK, Moertel CG, OConnell MJ, Schutt AJ, Rubin J, Hahn RG (1986) Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663
32. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, Goede A, Caplin M, Wiedenmann B (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinol 80:394
33. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, Oates J. (1993) Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 32:217
34. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Öberg K. (1997) Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogues. Acta Oncol 36:607
35. Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Öberg KE, Eriksson BK (2004) High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 151:115
36. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L (1999) Octreotide acetate long-acing formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17:600
37. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P (2000) Treatment of carcinoid syndrome. A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88:770
38. Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF (2000) Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 11:1127
39. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707
40. Kvols L, Öberg K, de Herder W, Anthony L, Glusman JE, Reha A, Tran LL, Wiedenmann B (2005) Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. Program of the 41st Annual meeting of the American Society of Clinical Oncology, Orlando, Florida, (abstract no. 8024)
41. Tiensuu Janson EM, Ahlstrom H, Andersson T, Öberg KE (1992) Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28A:1647
42. Kölby L, Persson G, Franzén S, Ahrén B (2003) Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumors. Br J Surg 90:687
43. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R (1999) Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 94:1381
44. Faiss S, Pape UF, Böhmig M, Dorrffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the international lanreotide and interferon study group. J Clin Oncol 21:2689
45. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C, Caron P (2005) Octreotide in insulinoma patients: Efficacy on hypoglycaemia, relationship with Octreotscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 152:757
46. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 41:1704-1713
47. Fjällskog ML, Ludvigsen E, Stridsberg M, Öberg K, Eriksson B, Janson ET (2003) Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med Oncol 20:59
48. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X, Epelbaum J (2003) Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: An in vivo and in vitro study. J Clin Endocrinol Metab 88:5353
49. Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, Jensen RT (2002) Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer; 94:331
50. Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV (1996) The glucagonoma syndrome: Clinical and Patologic features in 21 patients. Medicine 75:53
51. Angeletti S, Corleta VD, Schillaci O, Marignani M, Annibale B, Moretti A, Silecchia G, Scopinaro F, Basso N, Bordi C, Della Fave G. (1998) Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 42:792
52. Wymenga ANM, Eriksson B, Salmela PI, Jacobsen MB, van Cutsem EJDG, Fiasse RH, Välimäki MJ, Renstrup J, de Vires EGE, Öberg KE (1999) Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 17:1111
53. Santangelo WC, O'Dorisio TM, Kim JG, Severino G, Krejs GJ. (1985) Pancreatic cholera syndrome: Effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann Intern Med 103:363
54. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Neuhaus C, Jurgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ (1996) Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38:430